Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy

Yong-Chul Kim¹, Ho Jun Chin¹,²,³, ⁴*, Ho Suk Koo², Suhnggwon Kim¹,³,⁴

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, ² Department of Internal Medicine, Seoul National University Bundang Hospital, Seong-Nam, Korea, ³ Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, ⁴ Renal Institute, Seoul National University Medical Research Center, Seoul, Korea

Abstract

Background: Treatment remains uncertain for IgA nephropathy patients with mild to moderate proteinuria, for whom antihypertensive medication or the RAS blocker is not applicable due to low blood pressure.

Trial design: A double blinded randomized trial.

Methods: The anti-proteinuric effect of tacrolimus was explored for 40 biopsy-proven mild IgA nephropathies for 16 weeks. We randomly assigned patients either to receive tacrolimus or placebo with stratification by using a renin angiotensin system blocker. The primary outcome was the percentage change of final UACR compared to the baseline value (pcUACR).

Results: The mean value of pcUACR at 12-week and 16-week visits (primary outcome) was decreased more in the Tac group compared to the control group (-52.0±26.4 vs -17.3±29.3%, p = 0.001). At each visit, pcUACR was also decreased more in the Tac group compared to the control group. In the Tac group, the pcUACRs were -60.2±28.2%, -62.2±33.9%, -48.5±29.8%, and -55.5±24.0%, and, in the control group, -6.8±32.2%, -2.5±35.9%, -12.7±34.2%, and -21.9±30.6%, at 4-week, 8-week, 12-week, and 16-week visits, respectively. The pre-defined secondary outcomes were better in the Tac group compared to the control group. The frequency of decrease in pcUACR and percentage change of UPCR (pcUPCR) ≥50% at 16 weeks were 65.0% (13/20) and 55.0% (11/20) in the Tac group, and 25.0% (5/20) and 15.0% (3/20), in the control group, respectively (p = 0.025 for pcUACR and p = 0.019 for pcUPCR). However, tacrolimus wasn’t effective with a dose of 0.05 mg/kg/day in patients taking ARB. The adverse events were tolerable.

Conclusion: Tacrolimus effectively reduced proteinuria in IgA nephropathy with normal blood pressure. This suggested that tacrolimus could be an alternative to corticosteroid and RAS blocker for IgA nephropathy patients who cannot endure antihypertensive medication.

Trial Registration: Clinicaltrial.gov NCT1224028.

Introduction

IgA nephropathy is the most common glomerulonephritis among patients with renal biopsy in Korea [1,2] as well as in the other countries [3]. In Korea, the incidence of IgA nephropathy among renal biopsies has been increasing over the last 20 years [1], and the estimated cumulative incidence of end stage renal disease (ESRD) is 32.8% for 13 years after renal biopsy [2], which does not significantly differ from other reports in Western countries [4].

The most important clinical parameters to determine the prognosis in IgA nephropathy are proteinuria, hypertension, and glomerular filtration rate (GFR) [5]. Proteinuria was a more important risk factor compared to GFR, represented by serum creatinine in normotensive IgA nephropathy [6]. Many researchers reported the meaningful cutoff criteria of proteinuria was 1 g/day [5,7–11] as the risk for ESRD, but another report suggested proteinuria >0.5 g/day increased the risk [12]. Furthermore, several reports suggested early or mild IgA nephropathy with...
minimal or no proteinuria was not benign, especially in Asians [13,14]. A report from a study carried out in China stated that, among IgA nephropathy patients with proteinuria of <0.4 g/day, GFR ≥90 ml/min/1.73 m², and normotension, proteinuria increased in 46% of patients, hypertension was developed in 38%, and renal insufficiency in 24% during the mean follow-up duration of 111 months [13]. In another report from a study in Hong Kong, proteinuria of >1 g/day developed in 33% of patients, hypertension in 26%, and renal insufficiency (GFR <70 ml/min/1.73 m²) in 7% during the median follow-up of 7 years in IgA nephropathy patients with proteinuria of <0.4 g/day, normal renal function, and normotension [14].

An optimized supportive therapy is the key strategy for IgA nephropathy patients at risk of progression [5], in which the renin-angiotensin-system (RAS) blocker is the most important non-immunosuppressive treatment [5]. However, treatment is uncertain for IgA nephropathy patients with mild to moderate proteinuria, for whom anti-hypertensive medication or the RAS blocker is not applicable because of low blood pressure. While the currently suggested therapy for the proteinuric patients, despite receiving optimized supportive care, is corticosteroid, most studies included patients with moderate to severe proteinuria who were being administered RAS blocker, and/or hypertension [15,16] and it is not clear whether corticosteroid therapy would effectively compensate for the adverse events to prevent renal deterioration in patients with mild to moderate proteinuria and normal blood pressure.

Recently, Zhang et al. improved proteinuria of 14 refractory IgA nephropathy patients who were receiving tacrolimus and moderate doses of prednisolone [17]. They showed that the expression of synaptopodin and calciumurin in renal tissue from the patients was partially normalized after treatment, which was reported as the non-immunological effects of tacrolimus [18], and suggested tacrolimus could improve proteinuria without serious adverse events in IgA nephropathy [17].

Therefore, we tried to verify the anti-proteinuric effect of tacrolimus for IgA nephropathy patients with normotension or normal blood pressure with a RAS blocker, normal renal function, and mild to moderate proteinuria, who were not able to tolerate additional anti-hypertensive or RAS blockers for a short-term period.

**Materials and Methods**

**Trial design**

The protocol for this trial and supporting CONSORT checklist are available as supporting information: see Checklist S1 and Protocol S1. This study was a double blind randomized controlled clinical trial and was performed in a single center (clinicaltrial.gov identifier: NCT01224028). The protocol was approved by the Institutional Review Board of Seoul National University Hospital (IRB number: H-1002-032-309). There was no change of methods after trial commencement to declare. After obtaining written informed consent from all participants, we randomized patients 1:1 to a control group (placebo) or to a Tac group who had received tacrolimus, in a double blind manner and stratified according to using a RAS blocker, using the computer-generated randomization lists by the independent statistical committee from the researcher (doctors, nurses, and pharmacists related to this study) and patients. We followed the patients at 1 week, 4 weeks, 8 weeks, 12 weeks, and 16 weeks after a baseline visit for randomization.

**Participants**

The inclusion criteria were a biopsy proven IgA nephropathy, aged ≥18 and <70 years, serum creatinine ≤1.5 mg/dL or estimated GFR ≥60 ml/min/1.73 m², urine albumin to creatinine ratio (UACR) ≥3.0 and <30.0 g/g creatinine, and blood pressure (BP) <130/80 mmHg during the 3-month period before randomization. The GFR was estimated by the equation of the 2009 CKD-EPI creatinine equation [19]. We excluded the

---

**Figure 1. Study algorithm.** One patient in the control group withdrew at the 8-week visit because of the addition of a prohibited drug in another department, one patient in the Tac group withdrew at day 1 after enrollment because of pregnancy and had taken only 2 mg of tacrolimus, and another patient in the Tac group withdrew at the 4-week visit because of general weakness and myalgia related to medication.

doi:10.1371/journal.pone.0071545.g001
patients with ≥20% variations of BPs, UACRs, serum creatinines during 3 months before randomization, or with potassium sparing diuretics, corticosteroid, immunosuppressive medication, omega-3 fatty acid, or two or more medications of renin angiotensin system blocker (RAS blocker). We permitted the use of one RAS blocker drug, although we did not allow any change of medication and dose of medication during 3-month period before and after

Table 1. The basal characteristics of patients.

| At screening visits during 3 months before randomization | Control (20) | Tac (20) | p-value |
|----------------------------------------------------------|--------------|----------|---------|
| Hypertension (%)                                         | 7 (35.0)     | 9 (45.0) | 0.748   |
| Diabetess Mellitus (%)                                   | 0 (0.0)      | 1 (5.0)  | 1.000   |
| DBP (mmHg)*                                              | 73±5         | 73±5     | 0.775   |
| SBP (mmHg)*                                              | 119±6        | 118±7    | 0.603   |
| Creatinine (mg/dL)                                       | 0.98±0.24    | 1.05±0.29| 0.452   |
| GFR (ml/min/1.73 m²)                                     | 83.3±22.4    | 80.1±21.5| 0.645   |
| UACR (mg/g cr)*                                          | 910±561      | 975±450  | 0.692   |
| UPCR (mg/g cr)*                                          | 1193±664     | 1291±535 | 0.609   |

| At enrollment visit                                      |              |          |         |
|----------------------------------------------------------|--------------|----------|---------|
| Hypertension (%)                                         | 7 (35.0)     | 9 (45.0) | 0.748   |
| Diabetess Mellitus (%)                                   | 0 (0.0)      | 1 (5.0)  | 1.000   |
| DBP (mmHg)*                                              | 23.3±4.5     | 22.5±3.8 | 0.574   |
| SBP (mmHg)                                               | 74±6         | 73±3     | 0.775   |
| Creatinine (mg/dL)                                       | 0.98±0.26    | 1.06±0.30| 0.379   |
| GFR (ml/min/1.73 m²)*                                    | 84.6±23.2    | 79.6±21.6| 0.482   |

| Pathologic findings by Oxford classification*             |              |          |         |
|----------------------------------------------------------|--------------|----------|---------|
| Hematuria*                                                | 15 (75.0)    | 13 (65.0)| 0.490   |
| M score (1, %)                                            | 11 (64.7)    | 5 (31.3) | 0.055   |
| S score (1, %)                                            | 12 (70.6)    | 14 (87.5)| 0.235   |
| E score (1, %)                                            | 2 (11.8)     | 6 (37.5) | 0.118   |
| T score                                                  | 14 (82.4)    | 11 (68.8)| 0.607   |

*Tac: patients with tacrolimus. DBP: diastolic blood pressure. SBP: systolic blood pressure. GFR: calculated with 2009 CKD-EPI creatinine equation. UACR: urine albumin to creatinine ratio in mg/g creatinine unit. UPCR: urine protein to creatinine ratio in mg/g creatinine unit. RAS blocker: renin angiotensin system blocker using angiotensin II type I receptor blocker (ARB). Duration of illness: time-duration from renal biopsy to this clinical trial. BMI: body mass index. Hematuria: RBC 5 or more examined in 400-fold fields by light microscopic examination. Pathologic findings by Oxford classification: retrospectively reclassified findings in 33 patients using Oxford classification of IgA nephropathy.

doi:10.1371/journal.pone.0071545.t001
randomization. Other exclusion criteria were pregnancy or secondary IgA nephropathy.

Interventions

The initial dose of tacrolimus was 0.1 mg/kg/day administered orally in two divided doses and was titrated to maintain trough levels at 5–10 ng/ml at each visit after randomization. If the level was ≥15 ng/ml, we stopped tacrolimus for 2 weeks and then re-measured the trough level to adjust the dosage as described above. The level of tacrolimus was not given to the patient or the researcher but only to the statistitical committee member in charge of this study who decided on the dose of tacrolimus or placebo and notified such to the pharmacist at each visit before prescription. For adjusting the dose of placebo, the committee member should change the number of placebo capsules for the patient in the control group in the same manner as the adjustment of medication for the patient with tacrolimus who visited on the most recent day with a random allocation (no change, increase or decrease of dose, or discontinue of prescription). After 8 weeks of randomization, we reduced the dose of tacrolimus to 0.05 mg/kg/day or to half of the

Figure 2. The percentage changes of UACR and UPCR at each visit compared to the baseline level. 2A. Percent changes of UACR. 2B. Percent changes of UPCR. Baseline UACR or UPCR; mean value of UACR or UPCR at screening period and randomization. Final; mean value of UACR at 12 weeks and 16 weeks. The bar in each bar graph is the 95% confidence interval of mean value of the percent change of UACR or UPCR at each visit compared to baseline level. * p-value <0.001, **p<0.01, *** p = 0.001 by Student t-test for percent change of UACR or UPCR between control and Tac groups at each visit.

doi:10.1371/journal.pone.0071545.g002
Outcomes

We defined the baseline value of UACR or UPCR as the mean value of UACR or UPCR during the 3-month screening period and at visit 1 for randomization. The final level of UACR was defined as the mean value of UACR at 12-week and 16-week visits. The primary outcome was defined as the percent change (%) of final UACR (pcUACR) compared to the baseline value [100 x (final UACR - baseline UACR)/baseline UACR]. We defined several secondary outcomes related to the percentage changes of UACR and UPCR (pcUPCR). There was no changes of outcome-criteria.

**Sample size**

We estimated the sample size based on previous studies [20–24] that showed the mean pcUACR 35.4% (standard deviation, 36.7%). For comparison of the control and Tac groups at a level of significance of 5% (α-error = 0.05), we calculated that at least 17 patients were needed in each group to have 80% percent power (β-error = 0.20). We allocated 20 patients to each group with an estimated ≤15% drop-out rate.

**Statistical analysis**

Analysis of primary and secondary outcomes was by intention-to-treat (ITT). For statistical analysis, we used a paired or unpaired Student t-test for continuous variables and Pearson’s Chi-square test or Fisher’s exact test for qualitative variables. The data throughout the follow-up period were analyzed with the ANOVA for repeated measurements. When we compared parameters between Tac and control groups in each follow-up period during 5 visits, we used the Bonferroni correction for the criterion of significant difference between groups as p-value <0.01 (0.05/5).

---

**Table 2. The change of absolute values of blood pressures, serum creatinine, GFR, UACR, and UPCR during follow-up period.**

|                | V1 (0 week) | V3 (4 weeks) | V4 (8 weeks) | V5 (12 weeks) | V6 (16 weeks) | p-value* |
|----------------|-------------|--------------|--------------|---------------|---------------|----------|
| DBP (mmHg)    | Tac         | 72±3         | 75±7         | 76±6          | 74±7          | 75±5     |
|                | Control     | 74±6         | 77±9         | 74±8          | 77±7          | 73±9     | 0.635   |
| p-value**      | 0.138       | 0.438        | 0.347        | 0.250         | 0.747         |          |
| SBP (mmHg)    | Tac         | 117±8        | 122±11       | 122±11        | 124±6         | 122±9    |
|                | Control     | 120±7        | 121±25       | 123±10        | 122±8         | 120±11   | 0.925   |
| p-value**      | 0.192       | 0.911        | 0.860        | 0.512         | 0.381         |          |
| Creatinine (mg/dL) | Tac   | 1.06±0.30    | 1.17±0.32    | 1.18±0.33     | 1.13±0.36     | 1.10±0.32 |
|                | Control     | 0.98±0.26    | 0.97±0.27    | 0.96±0.28     | 1.02±0.29     | 0.99±0.27 |
| p-value**      | 0.355       | 0.048        | 0.033        | 0.332         | 0.291         |          |
| GFR (ml/min/1.73 m²) | Tac | 79.6±21.6    | 71.5±21.4    | 70.4±21.0     | 75.8±23.0     | 77.4±22.9 |
|                | Control     | 84.6±23.2    | 84.4±24.7    | 85.6±24.1     | 80.2±25.4     | 83.1±24.1 |
| p-value**      | 0.637       | 0.101        | 0.049        | 0.582         | 0.472         |          |
| UACR (mg/g cr) | Tac         | 1098±635     | 405±383      | 343±284       | 538±493       | 601±565  |
|                | Control     | 965±459      | 841±415      | 898±524       | 779±426       | 700±386  | 0.021   |
| p-value**      | 0.943       | 0.002        | <0.001       | 0.120         | 0.071         |          |
| UPCR (mg/g cr) | Tac         | 1398±809     | 501±425      | 458±317       | 761±590       | 863±798  |
|                | Control     | 1202±500     | 1061±531     | 1191±707      | 1071±497      | 973±471  | 0.009   |
| p-value**      | 0.912       | <0.001       | <0.001       | 0.092         | 0.033         |          |
| Trough level of tacrolimus (ng/ml) | Tac | 6.56±2.95봐 | 6.42±3.53봐 | 6.40±4.17     | 3.09±1.87     | 0.001   |

*p-value between control and Tac group by repeated measured ANOVA during follow-up period.

**p-value <0.001 compared to trough level of tacrolimus at visit 6 by posthoc analysis in a repeated measured ANOVA.

**p-value by Student t-test. The significant difference was considered as p-value <0.01 by Bonferroni correction.

The dose of tacrolimus was decreased from 0.025 mg/kg bid per day to 0.025 mg/kg bid per day after 8 week visit.

*The dose of tacrolimus was decreased from 0.05 mg/kg bid per day to 0.025 mg/kg bid per day after 8 week visit.

doi:10.1371/journal.pone.0071545.t002

---

Figure 3. The frequency of decrease in UACR and UPCR at 16 weeks as secondary outcomes. Outcome Aa and Ap: frequency of decrease in UACR and UPCR ≥30% at 16 weeks, compared to baseline level. Outcome Ba and Bp: frequency of decrease in UACR and UPCR ≥50% at 16 weeks compared to baseline level. Outcome Ca and Cp: frequency of decrease in UACR and UPCR ≥70% at 16 weeks. Outcome Da and Dp: frequency of outcome B and/or C. *p<0.01, **p<0.001; difference of frequency between groups.

doi:10.1371/journal.pone.0071545.g003
**Results**

The patients were enrolled from 26\textsuperscript{th} Nov. 2010 to 15\textsuperscript{th} Feb. 2011. Among 42 eligible patients with IgA nephropathy, 40 patients were allocated to control group (20 patients including 9 using a RAS blocker) or Tac group (20 patients including 11 using a RAS blocker) with stratification according to using RAS blocker except 2 patients unwilling to participate in this study (Figure 1). Kidney biopsy was performed 45.2±57.8 months before the study (ranging from 0 to 243 months). The RAS blockers which patients had been taking were angiotensin II type I receptor blockers (ARBs); eleven patients with valsartan (one patient with 40 mg/day and ten patients with 80 mg/day), eight patients with candesartan (one patient with 4 mg/day and seven patients with 8 mg/day), and one patient with losartan (50 mg/day). In the control group, one patient was excluded because they had taken potassium sparing diuretics in the other clinic at an 8-week visit, while in the Tac group, one patient declined the consent because of general weakness and myalgia at a 4-week visit and the other patient was withdrawn at day 1 after enrollment because of a positive result for pregnancy screening. She was unaware of her pregnant status and had taken 2 mg of tacrolimus. The compliance to take placebo or tacrolimus was 91.3±10.3% in the control group and 91.5±7.4% in the Tac group and did not differ between groups.

---

**Table 3.** The clinical results of patients stratified with ARB medication at randomization.

| Symptom | Patients without ARB* | | Patients with ARB* |
|---------|----------------------|----------------------|
|         | Control (n = 11) | Tac (n = 8) | p-value | Control (n = 8) | Tac (n = 10) | p-value |
| Percent changes of UACR* | | | | | | |
| At 4 weeks | –10.9±21.5 | –74.4±18.3 | <0.001 | –1.2±44.4 | –48.8±30.3 | 0.015 |
| At 8 weeks | –12.8±26.2 | –70.5±32.8 | 0.001 | 11.6±44.0 | –55.6±35.0 | 0.002 |
| At 12 weeks | –14.5±31.6 | –64.7±15.7 | 0.001 | –10.4±39.6 | –35.5±32.7 | 0.160 |
| At 16 weeks | –13.6±27.8 | –60.0±31.9 | 0.001 | –29.4±32.5 | –41.3±25.8 | 0.372 |
| Final value* | –14.0±26.6 | –67.4±12.4 | 0.003 | –21.8±34.2 | –39.6±28.6 | 0.246 |

**Table 4.** Adverse reactions during study.

| Symptom | Control | Tac |
|---------|---------|-----|
| Number of events | 15 | 49 |
| Cardiovascular | 1 | 2 |
| Gastrointestinal | 4 | 21 |
| Genitourinary | 0 | 4 |
| Hematologic | 0 | 1 |
| Musculoskeletal | 3 | 3 |
| Neurologic | 1 | 12 |
| Respiratory | 5 | 4 |
| Dermatologic | 1 | 2 |
| Severity | | |
| Mild | 15 | 43 |
| Moderate | 0 | 6 |
| Severe | 0 | 0 |
| Related to medication | 1 | 16 |
| Cessation of medication | 0 | 1 |

*ARB: Angiotensin II type I receptor blocker. Percent changes of UACR: calculated by level of UACR at each visit compared to level of baseline. Final value: mean value of UACR at 12 weeks and 16 weeks. Secondary outcome: levels of UACR or UPCR at 16 weeks compared to level of baseline. Baseline value: mean value of UACR or UPCR at screening period and randomization period (0 week).

doi:10.1371/journal.pone.0071545.t003

doi:10.1371/journal.pone.0071545.t004
Baseline characteristics

All parameters did not differ between the control and Tac groups at enrollment (Table 1). Among patients without a RAS blocker, only DBP in the Tac group was different compared to the control group (72 ± 3 vs 76 ± 4 mmHg, p = 0.029). Among patients with a RAS blocker, clinical characteristics did not differ between groups (all p > 0.1).

We re-analyzed the pathologic findings of 33 patients (82.5%) with Oxford classification of IgA nephropathy [25]. The frequency of patients with M1 score was slightly higher in control group (11/17 in control group vs 5/16 in Tac group) but was not significant (p = 0.055). Other findings including frequencies of S score (0, 1), E score (0, 1), and T score (0, 1, 2) were not different between groups (Table 1).

Primary outcome

The pcUACR at each visit compared to at baseline was calculated. The primary outcome, defined as the mean value of pcUACR at 12-week and 16-week visits, was decreased more in the Tac group compared to the control group (−52.0 ± 26.4 vs −17.3 ± 29.3%, p = 0.001). At each visit, pcUACR was also decreased more in the Tac group compared to the control group (Figure 2A). In the Tac group, the pcUACRs were −60.2 ± 28.2%, −62.2 ± 33.9%, −48.5 ± 29.8%, and −55.5 ± 24.0% at 4-week, 8-week, 12-week, and 16-week visits, respectively. The decreased amount of pcUACR at a 12-week visit, which was 4 weeks after decreasing the dose of tacrolimus from 0.1 mg/kg/day to 0.05 mg/kg/day, was lower than that of the 4-week visit (p = 0.030 by repeated measured ANOVA). However, the pcUACR at the 16-week visit did not differ from the pcUACR at the 4-week visit or at the 8-week visit (p > 0.05 by repeated measured ANOVA) in the Tac group. In the control group, pcUACRs were −6.8 ± 32.2%, −2.5 ± 35.9%, −12.7 ± 34.2%, and −21.9 ± 30.6% at 4-week, 8-week, 12-week, and 16-week visits, respectively. The decreased amount of pcUACR at the 16-week visit was greater than that of the 4-week visit in the control group (p = 0.032 by repeated measured ANOVA).

Secondary outcome

In the Tac group, the pcUPCRs were −61.1 ± 25.2%, −61.8 ± 26.4%, −41.8 ± 29.4%, and −49.7 ± 21.9% at 4-week, 8-week, 12-week, and 16-week visits, respectively. The decreased amount of pcUPCRs at the 12-week visit was lower than that at the 4-week or 8-week visits (p = 0.003 and p = 0.031 by repeated measured ANOVA, respectively) and the decreased amount of pcUPCRs at the 16-week visit was lower than that at the 4-week visit in the Tac group (p = 0.022 by repeated measured ANOVA). In the control group, pcUPCRs were −12.2 ± 23.1%, −0.98 ± 36.9%, −5.8 ± 37.2%, and −14.4 ± 40.0% at 4-week, 8-week, 12-week, and 16-week visits, respectively (Figure 2B). The pcUPCRs at each visit did not differ in the control group (p > 0.05 by repeated measured ANOVA, respectively). The pcUPCR at the 16-week visit in the Tac group decreased more than the control group (p = 0.004) and at each visit, pcUPCR decreased more in the Tac group compared to the control group (Figure 2B).

The pre-defined secondary outcomes were better in the Tac group than in the control group (Fig. 3). The frequencies of decrease in pcUACR and pcUPCR ≥50% at 16 weeks were 65.0% (13/20) and 55.0% (11/20) in the Tac group, and 25.0% (5/20) and 15.0% (3/20) in the control group (p = 0.025 for pcUACR and p = 0.019 for pcUPCR). The proportion of patients with UACR < 0.2 g/g cr at the 16-week visit tended to be greater in the Tac group (25.0%) compared to the control group (10.0%), although it did not show statistical significance.

Repeate measurements

Blood pressures between groups did not differ throughout the study period. The serum creatinine levels were higher at 4-week and 8-week visits in the Tac group than in the control group, although the p-values did not show significant differences with the criterion by Bonferroni’s correction. After the 8-week visit, the levels of creatinine did not differ between groups. The levels of UACR and UPCR were lower in the Tac group at 4-week and 8-week visits than in the control group. The serum trough level of tacrolimus was maintained within 5–10 ng/ml up to 8 weeks and then decreased along with a reduction of dosage (Table 2).

Outcomes according to ARB

We compared the outcomes between groups according to ARB use at randomization (Table 3). The results of pcUACR and pcUPCR at each visit were better in the Tac group than in the control group in patients without ARB medication, even with the p-value criterion of < 0.01 by Bonferroni’s correction. Among patients with ARB, the pcUACR and the pcUPCR decreased more in the Tac group than in the control group up to the 8-week visit and the difference was not apparent after the reduction of the tacrolimus dose, although the decreased amount of pcUACR or pcUPCR tended to be higher in the Tac group.

Adverse events

The frequency of adverse events was higher in the Tac group, although the severity of most events (43/49) was mild. The frequency of adverse events related to medication tended to be higher in the Tac group, but this was not significant (16/49 events in the Tac group vs 1/15 events in the control group). The symptoms related to tacrolimus were gastrointestinal discomforts, headache, tremor, and coldness of extremities. Only one patient should discontinue the tacrolimus because of general weakness and myalgia after 4-week medication. Newly onset diabetes mellitus (DM) among patients without DM at randomization, was observed in one patient in the tacrolimus group at the 16-week visit [fasting glucose (96 mg/dL) and HbA1c (6.7%)] (Table 4).

Discussion

We performed a double blinded randomized controlled study to verify anti-proteinuric effect of tacrolimus for IgA nephropathy patients with normotension or normal blood pressure, and mild to moderate proteinuria. Tacrolimus was effectively decreased proteinuria during 16 weeks, compared to placebo. The anti-proteinuric effect of tacrolimus was an additive to a RAS blocker and was dose dependent in patients with a RAS blocker.

We used the placebo as same capsules as the tacrolimus and adjusted the dose of placebo according to the change of tacrolimus dose to achieve complete double blindness for patients and researchers including pharmacists.

Proteinuria is a well-known prognostic factor for ESRD in IgA nephropathy. Traditionally, the prognostic importance of proteinuria was analyzed in gram unit/day [4,7–11]. The proteinuria amount of 1 g/day was the cutoff level to indicate a worse renal prognosis. However, several considerations are involved with this point of view. At first, IgA nephropathy with proteinuria < 1 g/day did not always indicate as benign. In Japan, renal insufficiency was developed during a mean follow-up period of 6.7 years in 17.2% of 203 IgA nephropathy patients with proteinuria 0.5–0.9 g/day and in 3.5% of 197 patients with proteinuria < 0.5 g/day.
day and GFR patients developed proteinuria among 177 IgA nephropathy patients with proteinuria developed hypertension, and 24% developed renal insufficiency in China, 46% of patients showed increased proteinuria, 38%, genetic susceptibility [5]. Secondly, as Reich et al. discussed, the term outcomes of IgA nephropathy with minimal or no period of 111 months [13]. However, in Caucasians, the long-term outcomes of IgA nephropathy with minimal or no proteinuria was excellent [26]. It is possible that the prognosis of IgA nephropathy among different races differs, partly because of genetic susceptibility [5]. Secondly, as Reich et al. discussed, the course of IgA nephropathy with initial proteinuria <1 g/day is variable according to the change of proteinuria during the follow-up period [27]. The greater increase in proteinuria, the worse the renal survival [27]. In another report, among 121 IgA nephropathy patients with proteinuria ≥1 g/day at presentation or during follow-up period, reduced proteinuria group (in which proteinuria was decreased to <1 g/day at last follow-up) showed better outcome compared to persistent proteinuria group and showed similar renal outcome as in low proteinuria group [7]. Therefore, it is necessary to reconsider the treatment strategy for patients with “low risk proteinuria” and complete or partial remission of proteinuria could be a target treatment to prevent renal progression.

The enrolled patients had proteinuria in spite of appropriate blood pressure with or without anti-hypertensive medication including a RAS blocker. We could not use the full dose of a RAS blocker or combination of RAS blockers because of the relatively low blood pressure. Until now, while no evident guidelines have been available to treat such patients, a high-dose corticosteroid is recommended [5]. Meta-analyses on the effectiveness of corticosteroid for IgA nephropathy showed that steroids provided renal protection but increased the risk of adverse events [15,16]. In this study, tacrolimus reduced proteinuria in IgA nephropathy patients. The anti-proteinuric effect of tacrolimus was observed as treating several renal diseases including nephrotic syndrome [28], primary glomerulonephritis [29], minimal change lesion [30], membranous nephropathy [31], lupus nephritis [32,33], and transplanted kidney [34] as well as IgA nephropathy [17]. The possible mechanism of the calcineurin inhibitor to reduce proteinuria is probably multifactorial, and mechanisms other than the immunosuppressive effects may be involved [31]. Zhang et al. demonstrated an increased expression of calcineurin and decreased synaptopodin were recovered after treatment with prednisolone and tacrolimus in renal tissue of IgA nephropathy [17]. They suggested that the anti-proteinuric effect of tacrolimus in IgA nephropathy would result from the stabilization of cytoskeleton in podocytes as the result of Faul’s works using cyclosporin [18]. The time required to achieve remission was less than 1 month in 7/9 patients [17]. We also observed that the amount of decrease in UPcCR was fully achieved in the short-term period, implying a long-term trial is needed with tacrolimus for IgA nephropathy and the appropriate dose of tacrolimus should be determined in further studies.

In conclusion, tacrolimus reduced proteinuria effectively and rapidly in IgA nephropathy with mild to moderate proteinuria and normal blood pressure in this short-term trial with double blinded randomization. This study suggested that tacrolimus could be an alternative to corticosteroid and RAS blocker for IgA nephropathy patients who are not able to tolerate anti-hypertensive medication.

Supporting Information

Protocol S1  Protocol for this clinical trial.

Checklist S1  CONSORT Checklist.

Acknowledgments

Yong-Chul Kim contributed to analysis the data, Ho Jun Chin, to design the study, analysis the data, and write the paper. Ho Suk Koo contributed to perform the study and Sunghywon Kim, to conceive, design, and perform the study. All authors revised the paper for important intellectual content and have seen and approved the final version.
Tacrolimus for IgA Nephropathy

Author Contributions
Conceived and designed the experiments: HJC SK. Performed the experiments: HSK SK. Analyzed the data: YCK HJC. Wrote the paper: HJC. Conceived and designed the experiments: HJC SK. Performed the experiments: HSK SK. Analyzed the data: YCK HJC. Wrote the paper: HJC. Revised the paper for important intellectual content and have seen and approved the final version: HJC YCK HSK SK.

References
1. Chang JH, Kim DK, Kim HW, Park SY, Yoo TH, et al. (2009) Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transplant 24(8): 2406-2410.
2. Lee H, Kim DK, Oh KH, Joo KW, Kim YS, et al. (2013) Mortality and renal outcome of primary glomerulonephritis in Korea: Observation in 1,943 biopsied cases. Am J Nephrol 37(1): 74-83.
3. D’Amico G (1987) The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64(245): 709-727.
4. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, et al. (2003) A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 18(3): 1541-1548.
5. Flege J, Eimer F (2011) Current therapy for IgA nephropathy. J Am Soc Nephrol 22(10): 1785-1794.
6. Koyama A, Igarashi M, Kobayashi M (1997) Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 29(4): 526-533.
7. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, et al. (2011) Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22(4): 752-761.
8. Li PK, Ho KK, Szeto CC, Yu L, Lai FM (2002) Prognostic indicators of IgA nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial Transplant 17(1): 64-69.
9. Lee H, Kim DK, Oh KH, Joo KW, Kim YS, et al. (2012) Mortality of IgA Nephropathy Patients. A Single Center Experience over 30 Years. PLoS One 7(12): e51225.
10. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8(2): 199-207.
11. Neelakantappa K, Gallo GR, Baldwin DS (1988) Proteinuria in IgA nephropathy. Kidney Int 33(3): 716-721.
12. Usui Y, Yamagata K, Kaki H, Ono T, Yamamoto S, et al. (2001) Heterogeneity of progression in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med 40(8): 697-702.
13. Shen P, He L, Huang D (2008) Clinical course and prognostic factors of clinical early IgA nephropathy. Neth J Med 66(6): 242-247.
14. Szeto CC, Lai FM, To KF, Wong TY, Chow KM, et al. (2001) The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med 110(6): 434-437.
15. TESTING Study Group; Lj J, Xu D, Perkovich V, Ma X, Johnson DW, et al. (2012) Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23(6): 1108-1116.
16. Zhou YH, Tang LG, Guo SL, Jin ZC, Wu MJ, et al. (2011) Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis. PLoS One 6(3): e16708.
17. Zhang Q, Shi SF, Zhu L, Li JC, Liu LJ, et al. (2012) Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. Am J Nephrol 35(4): 312-320.
18. Paul C, Donnelly M, Mersch-Sundermann V, Chang YH, Franz S, et al. (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14(9): 931-938.
19. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration); Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9): 664-672.
20. Nakamura T, Inose T, Sugaya T, Kawase Y, Suzuki T, et al. (2007) Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobulin A nephropathy. Am J Hypertens 20(11): 1195-1201.
21. Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K (2008) Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertension Res 31(9): 1711-1717.
22. Tomino Y, Kasawura T, Kimura K, Endoh M, Hossy T, et al. (2009) Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol 22(2): 224-231.
23. Ferraro PM, Ferracioli GF, Gambauro G, Fulignati P, Costanzo S (2009) Combined treatment with renin-angiotensin system blockers and polyanionicated fatty acids in proteinic IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 24(1): 156-160.
24. Horita Y, Tadokoro M, Taura K, Ashida R, Hsu M, et al. (2007) Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail 29(4): 441-446.
25. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Catran DC, Coppo R, Cook HT, Frehally J, Roberts IS, et al. (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76(5): 534-545.
26. Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN); Gutierrez E, Zamora I, Ballarin JA, Arce Y, Jimenez S, et al. (2001) Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 23(10): 1735-1760.
27. Toronto Glomerulonephritis Registry; Reich HN, Troyanov S, Scholey JW, Catran DC (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18(12): 3177-3183.
28. Fan L, Liu Q, Liao Y, Li Z, Ji Y, et al. (2012) Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. Int Urol Nephrol [Epub ahead of print].
29. Arikian H, Koc M, Cakalagoufoglu F, Eren Z, Segal MS, et al. (2008) Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. Nephrol Dial Transplant 23(5): 713-721.
30. Li X, Li H, Chen J, He Q, Le R, et al. (2008) Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 23(6): 1919-1925.
31. Chen W, Liu Q, Liao Y, Yang Z, Chen J, et al. (2013) Outcomes of Tacrolimus Therapy in Adults With Refractory Membranous Nephrotic Syndrome: A Prospective, Multicenter Clinical Trial. Am J Med Sci 345(2): 81-87.
32. Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furago I, et al. (2010) Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol 28(1): 6-12.
33. Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K (2008) Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertension Res 31(9): 1711-1717.
34. Lee T, Oh KH, Joo KW, Kim YS, Ahn C, et al. (2010) Tacrolimus is an alternative therapy option for the treatment of refractory lupus nephritis. Lupus 19(8): 974-980.
35. Boen JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, et al. (2001) Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transplant Int 14(6): 370-383.

Textor SC, Burnett JC Jr, Romero JC, Cazzanelli VJ, Talers SJ, et al. (1995) Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 47(5): 1426-1435.